Medicamen Biotech Limited has informed the Exchange that Board of Directors at its meeting held on May 30, 2025, recommended Final Dividend of 1 per equity share.
MEDICAMEQ · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.8 pts less than Nifty Microcap 250 and 2.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors of Medicamen Biotech Limited, at its meeting held on May 30, 2025, has recommended a Final Dividend of ₹1 per equity share for its shareholders. This is a dividend recommendation that typically requires shareholder approval at the Annual General Meeting before it can be paid out. The final record date and payment date will be communicated separately by the company.
The ₹1 per share dividend reflects a modest payout to shareholders. Without the current share price, the effective yield cannot be determined, but investors should note that the actual payout depends on future AGM approval and record date confirmation.